FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
June 15, 2015
Global agreement with IntriCon Corporation to expand GEMS™ WIN sales through access to new and cost-effective, wireless ECG devices.
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today announced it has entered into an ECG device and software distribution and marketing agreement with Minnesota based IntriCon Corporation ("IntriCon"; NASDAQ symbol "IIN").
CardioComm Solutions will benefit directly from devices sales as an authorized distributor of the Sirona devices with preferred distributor pricing which will translate into competitive pricing to the Company's Global ECG Management Solution for Windows ("GEMS™ WIN") customer base. Hardware sales will commence in Canada and the USA with the anticipation that the Sirona device will have the needed CE Mark provided for sales to be possible in Europe by the end of this year.
Under the agreement, CardioComm Solutions has developed a custom interoptability between IntriCon's Sirona ECG device and the Company's proprietary wireless GEMS™ WIN module and ("GEMS™ AIR"). This integration will allow GEMS™WIN licensors to incorporate the Sirona device into their business operations for use alongside their existing ambulatory ECG/arrhythmia monitoring device inventory. For customers under an active GEMS™ AIR software license, the appropriate Sirona driver version update will be provided at no cost.
What's new? In addition to supporting traditional trans-telephonic ECG transmission, the Sirona device can connect via Android and iPhone mobile devices allowing a patient's own Smartphone to support wireless transmission of their Sirona acquired ECG data. Use of patient Smartphones would provide savings opportunities for GEMS™ AIR customers who no longer would be required to purchase more expensive ambulatory ECG monitoring devices with built-in GSM capabilities. Where a patient does not have a Smartphone, operators may provide a locked Smartphone for use with the Sirona device, a common practice with ECG service providers.
The Sirona-GEMS™ based ECG management does not involve the storage of any patient data on the Smartphone at any time and will be available to the North American market prior to the end of Q3 2015. GEMS™ WIN is the only FDA cleared and Health Canada approved, ECG management software platform available for sale that supports the Sirona device in North America.
CardioComm Solutions has previously reported requirements for ECG service providers to replace their existing ECG management solutions to versions that are WIN 7 and Server 2008 compatible. CardioComm Solutions released its GEMS™ WIN software upgrade to the arrhythmia monitoring market in response to the 2014 discontinuation of XP support by Microsoft and the soon to occur discontinuation of Server 2003 in July, 2015. The GEMS™ WIN family of products is a Windows 7 and Server 2008 compatible version of the Company's FDA cleared, Health Canada approved and CE Marked ECG management software and includes a specific module (GEMS™ AIR) that enables the use of the Sirona as well and other digital wireless event recorders.
To learn more about the CardioComm Solutions products and devices compatible with GEMS™ WIN please see the Company's website www.cardiocommsolutions.com. or contact the Company at firstname.lastname@example.org.
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of